IPG 7236
Alternative Names: IPG-7236Latest Information Update: 23 Mar 2022
At a glance
- Originator Nanjing Amifei Biopharmaceutical Technology
- Developer Immunophage Biotech; Nanjing Amifei Biopharmaceutical Technology
- Class Antineoplastics; Small molecules
- Mechanism of Action CCR8 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 23 Mar 2022 Immunophage Biotech plans a phase I trial in Atopic Dermatitis (PO, Tablet) (NCT05288543), in April 2022
- 07 Dec 2021 IPG 7236 is available for licensing as of 07 Dec 2021. http://www.immunophage.com.cn/quanqiuhezuo.html
- 15 Nov 2021 Phase-I clinical trials in Solid tumours (Late-stage disease, Monotherapy, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) (NCT05142592)